COVID-19 Vaccination Rates in a Global HIV Cohort

Evelynne S. Fulda, Kathleen V. Fitch, Edgar T. Overton, Markella V. Zanni, Judith A. Aberg, Judith S. Currier, Michael T. Lu, Carlos Malvestutto, Carl J. Fichtenbaum, Esteban Martinez, Triin Umbleja, Pamela S. Douglas, Heather J. Ribaudo, Steven K. Grinspoon

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk.

Original languageEnglish
Pages (from-to)603-607
Number of pages5
JournalJournal of Infectious Diseases
Issue number4
StatePublished - 15 Feb 2022


  • COVID-19
  • Global Burden of Disease region
  • Human immunodeficiency virus
  • Vaccination


Dive into the research topics of 'COVID-19 Vaccination Rates in a Global HIV Cohort'. Together they form a unique fingerprint.

Cite this